Traws Pharma opened higher at $0.26, compared with its previous close of $0.25. In the last trading session, the stock traded between $0.25 and $0.30. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Traws Pharma is now worth
$ 1.34
Resulting in a loss of
$ 98.66 (98.66%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
+$0.04 (+14.80%)
Day High
$0.30
Day Low
$0.25
Day Open
$0.26
Prev Close
$0.25
Volume
6,60,684
1W Return
3.99%
1M Return
-31.83%
3M Return
-47.82%
6M Return
-85.79%
1Y Return
-84.81%
Fundamentals
Market Cap ($ Mn)
4
PE Ratio
-
PB Ratio
5.33
PEG Ratio
-
ROE
-
ROCE
133.33%
EPS (TTM)
$-0.17
Investment Returns
1 Week
3.99%
1 Month
-31.83%
3 Months
-47.82%
6 Months
-85.79%
9 Months
-85.21%
Financials
Quarterly
All values in $ Mn
0.1
Mar 25
2.7
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
12Nov
Traws Pharma reports positive Phase 2a data for COVID-19 drug
Ratutrelvir showed symptom resolution comparable to Paxlovid in Phase 2a. No viral rebound observed through Day 28 in 92-patient study. Fewer treatment-related adverse events vs Paxlovid in eligible subjects. TXM compressed tablet bridging study achieved objectives. TXM regulatory resubmission planned for Q4 2026.
Traws Pharma posted a Q2 EPS of $(0.16), beating the $(0.34) estimate by 51.52%. However, this reflects a 45.45% increase in losses compared to $(0.11) per share in the prior year quarter, indicating widening deficits despite outperforming conservative market forecasts.
3mo ago
2Jul
Traws Pharma files prospectus for $139.2M mixed shelf offering
Traws Pharma filed a prospectus for a mixed shelf offering of up to $139,185,641.25, including common stock, preferred stock, debt securities, warrants, and units. The company's stock trades on The Nasdaq Capital Market under TRAW, closing at $0.82 on June 29, 2026.
4mo ago
22Jun
Traws Pharma prepares MHRA resubmission for influenza study
Traws Pharma is developing an updated toxicology data package to meet MHRA requirements for its Phase 2a human influenza challenge study of tivoxavir marboxil. The company plans to resubmit the data in Q3 2026, expecting a response within 30 days. Executives highlighted the drug's efficacy profile and the critical need for treatments for vulnerable populations.
4mo ago
18Jun
HC Wainwright downgrades Traws Pharma to Neutral, sets $1 target
HC Wainwright & Co. analyst Brandon Folkes downgraded Traws Pharma from Buy to Neutral and announced a $1 price target.
4mo ago
15Jun
Ladenburg Thalmann downgrades Traws Pharma to Neutral
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Traws Pharma from Buy to Neutral, revising the investment stance on the NASDAQ-listed company.
